Actively Recruiting
Long-Term Follow-Up of Ibrutinib and Venetoclax Treatment in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Led by European Research Initiative on CLL · Updated on 2026-08-19
323
Participants Needed
1
Research Sites
350 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who were treated with a combination of two drugs, ibrutinib and venetoclax, in the original CAPTIVATE clinical trial. The study aims to understand patients health after completing this initial treatment, focusing on the types and frequency of second-line treatments if the disease returns, long-term safety and effectiveness of the initial drugs, and how resistance to these treatments may develop over time. This is an observational study where patients are monitored during their regular medical care without receiving new experimental treatments. Patients will be followed for up to 10 years to track disease status, treatment history, new health issues, and survival. With extra consent, blood samples may be collected every six months to detect very small amounts of remaining cancer cells and to analyze genetic mutations if the disease progresses. Participants will be involved in long-term health monitoring through routine care visits. Researchers will collect data annually on second-line treatments, response rates, survival, adverse events, and other health changes. Optional blood tests for measurable residual disease and genetic analysis may occur. Participation is voluntary, and patients can withdraw or decline specific tests anytime without affecting their usual medical care.
CONDITIONS
Brief Title
Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL
Research Team
P
Paolo Ghia, Prof
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here